KRAS and familial pancreatic carcinoma: In addition, our research team identified several unique compounds with potent anticancer activities against colon cancer cells (Cruz-Nova et al, 2018, 2022) and pancreatic cancer cells (Casique-Aguirre et al, 2018; Paola et al, 2020), disrupting the KRas signaling pathway and producing specific cell death via apoptosis.